Results 81 to 90 of about 5,151 (200)
, 2009 This issue of eMedRef provides information to clinicians on the pathophysiology, diagnosis, and therapeutics of ...
Brill, John
core +1 more source
Clinical Pharmacology &Therapeutics, Volume 117, Issue 3, Page 846-856, March 2025.Daprodustat, a novel oral hypoxia‐inducible factor prolyl hydroxylase inhibitor is approved in the United States for the treatment of anemia due to chronic kidney disease (CKD) in adults receiving dialysis for at least 4 months. Pharmacodynamic dose‐hemoglobin (Dose‐Hgb) models were developed as daprodustat progressed through development.
Kelly M. Mahar +5 more
wiley +1 more source
An Exploratory Analysis of Pharmaceutical Price Disparities and Their Implications Among Six Developed Nations [PDF]
, 2006 In our study of 43 drugs, prescription drug prices in several wealthy nations (Australia, Canada, France, Germany, and the U.K.) were much lower than in the U.S. on average, well below relative per capita GDP. There was relatively little difference among
Elizabeth DuPre +2 more
core
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained. [PDF]
, 2018 High-quality, safe, and effective biosimilars have the potential to increase access to biological therapies worldwide and to reduce cancer care costs.
Aapro, Matti +3 more
core +1 more source
“Spot Diagnosis”: Typical Endoscopic and Histopathological Features of Pseudomelanosis duodeni
Clinical Case Reports, Volume 13, Issue 2, February 2025.ABSTRACT Pseudomelanosis duodeni is a rare yet benign endoscopic entity characterized by black‐brown pigmentation of the duodenal mucosa secondary to iron accumulation within lamina propria macrophages. Histopathological evaluation of duodenal biopsies is reliable in excluding important differential diagnoses and preventing unnecessary investigations ...
Christopher James Shephard, Bulent Baran
wiley +1 more source
The use of darbepoetin alpha in infants
Сеченовский вестник, 2019 Among the somatic pathology in young children, the most common is anemic syndrome. Until recently, the commonest method for correction of anemia was hemotransfusion, which allows to restore normal hemoglobin quickly, but has the high risk of ...
A. V. Shchegolev +4 more
doaj +1 more source
Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
International Journal of Nephrology and Renovascular Disease, 2014 Javier Arrieta,1 Iñigo Moina,1 José Molina,2 Isabel Gallardo,3 María Luisa Muñiz,4 Carmen Robledo,5 Oscar García,5 Fernando Vidaur,6 Rosa Inés Muñoz,3 Izaskun Iribar,7 Román Aguirre,7 Antonio Maza8 ...
Arrieta J +11 more
doaj
Качественная клиническая практика, 2018 Goal: to conduct pharmacoeconomic analysis of using the darbepoetin alfa (Aranesp) and other erythropoiesis-stimulating agents for anemia correction in patients on hemodialysis or peritoneal dialysis. Methodology.
I. S. Krysanov +2 more
doaj
International Brazilian Journal of UrologyObjectives: To evaluate protective effects of darbepoetin and tadalafil against ischemia-reperfusion injury in ipsilateral and contralateral testicle. Materials and Methods: Thirty 3-month-old adult male Wistar-Albino rats were randomly divided into 5 ...
Caglar Yildirim +5 more
doaj +1 more source
BMC Nephrology, 2019 Background Darbepoetin alfa (DA-α) is a long-acting erythropoiesis-stimulating glycoprotein which has half-life three-fold longer than that of Erythropoietin alfa (EPO). The objective of this study was to compare the efficacy and safety of DA-α injection
Shubhadeep D. Sinha +9 more
doaj +1 more source